Efficacy and safety of rituximab in the treatment of refractory myasthenia gravis: Meta-analysis | |
Shan-shan CHU; Deng CHEN; Li-na ZHU; Ge TAN; Da XU; Hai-jiao WANG; Yu ZHANG; Ling LIU | |
刊名 | Chinese Journal of Contemporary Neurology and Neurosurgery |
2018 | |
卷号 | Vol.18 No.7页码:494-500 |
关键词 | Myasthenia gravis Receptors, cholinergic Receptor protein ⁃ tyrosine kinases Meta⁃analysis |
ISSN号 | 1672-6731 |
URL标识 | 查看原文 |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/1823180 |
专题 | 四川大学 |
作者单位 | Department of Neurology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China Department of Neurology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China Department of Neurology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China Department of Neurology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China Department of Neurology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China Department of Neurology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China Department of Neurology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China Department of Neurology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China |
推荐引用方式 GB/T 7714 | Shan-shan CHU,Deng CHEN,Li-na ZHU,et al. Efficacy and safety of rituximab in the treatment of refractory myasthenia gravis: Meta-analysis[J]. Chinese Journal of Contemporary Neurology and Neurosurgery,2018,Vol.18 No.7:494-500. |
APA | Shan-shan CHU.,Deng CHEN.,Li-na ZHU.,Ge TAN.,Da XU.,...&Ling LIU.(2018).Efficacy and safety of rituximab in the treatment of refractory myasthenia gravis: Meta-analysis.Chinese Journal of Contemporary Neurology and Neurosurgery,Vol.18 No.7,494-500. |
MLA | Shan-shan CHU,et al."Efficacy and safety of rituximab in the treatment of refractory myasthenia gravis: Meta-analysis".Chinese Journal of Contemporary Neurology and Neurosurgery Vol.18 No.7(2018):494-500. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论